Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic

International Journal of Drug Policy

Volumn 46, Issue , 2017, Pages 172-179

  Fairbairn, Nadia ^a,b   Coffin, Phillip O ^c,d   Walley, Alexander Y ^e  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fentanyl; Naloxone; Overdose; Synthetic opioids

Indexed keywords

DIAMORPHINE; FENTANYL; ILLICIT DRUG; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; STREET DRUG;

DRUG EFFICACY; DRUG EXPOSURE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG POTENCY; EPIDEMIC; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MEDICAL TECHNOLOGY; NOTE; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SCALE UP; SOCIAL NETWORK; COMMUNITY CARE; COMPLICATION; DRUG DEPENDENCE; HEROIN DEPENDENCE; OPIATE ADDICTION; TRENDS;

ANALGESICS, OPIOID; COMMUNITY HEALTH SERVICES; DRUG OVERDOSE; FENTANYL; HEROIN; HEROIN DEPENDENCE; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 85021767354     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.06.005     Document Type: Note

References (98)

1. Albert, S., Brason, F.W. 2nd, Sanford, C.K., Dasgupta, N., Graham, J., Lovette, B., Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Medicine 12:Suppl. 2 (2011), S77–S85, 10.1111/j.1526-4637.2011.01128.x.
2. Amlani, A., McKee, G., Khamis, N., Raghukumar, G., Tsang, E., Buxton, J.A., Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada. Harm Reduction Journal, 12, 2015, 54, 10.1186/s12954-015-0088-4.
3. Arens, A.M., van Wijk, X.M., Vo, K.T., Lynch, K.L., Wu, A.H., Smollin, C.G., Adverse effects from counterfeit alprazolam tablets. JAMA Internal Medicine 176:10 (2016), 1554–1555, 10.1001/jamainternmed.2016.4306.
4. Armenian, P., Olson, A., Anaya, A., Kurtz, A., Ruegner, R., Gerona, R.R., Fentanyl and a novel synthetic opioid U-47700 masquerading as Street Norco in Central California: A case report. Annals of Emergency Medicine 69:1 (2017), 87–90, 10.1016/j.annemergmed.2016.06.014.
5. Beacon Dispatch Community-based overdose response. (2017).
6. Behar, E., Rowe, C., Santos, G.M., Coffa, D., Turner, C., Santos, N.C., Coffin, P.O., Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain. Journal of General Internal Medicine 32:3 (2016), 291–295, 10.1007/s11606-016-3911-z.
7. Bird, S.M., McAuley, A., Perry, S., Hunter, C., Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: A before (2006–2010) versus after (2011–2013) comparison. Addiction 111:5 (2016), 883–891, 10.1111/add.13265.
8. Bohnert, A.S., Bonar, E.E., Cunningham, R., Greenwald, M.K., Thomas, L., Chermack, S., Walton, M., A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose. Drug and Alcohol Dependence 163 (2016), 40–47, 10.1016/j.drugalcdep.2016.03.018.
9. Bounthavong, M., Harvey, M.A., Wells, D.L., Popish, S.J., Himstreet, J., Oliva, E.M., Christopher, M.L., Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis. Journal of the American Pharmaceutical Association, 2017, 2003, 10.1016/j.japh.2016.11.003.
10. Brecher, E.M., The consumers union report on licit and illicit drugs., 1972, Little, Brown & Co, Boston.
11. Brodrick, J.E., Brodrick, C.K., Adinoff, B., Legal regimes surrounding naloxone access: Considerations for prescribers. American Journal of Drug and Alcohol Abuse 42:2 (2016), 117–128, 10.3109/00952990.2015.1109648.
12. Brunt, T.M., Nagy, C., Bucheli, A., Martins, D., Ugarte, M., Beduwe, C., Ventura Vilamala, M., Drug testing in Europe: Monitoring results of the Trans European Drug Information (TEDI) project. Drug Testing and Analysis 9:2 (2017), 188–198, 10.1002/dta.1954.
13. Burns, G., DeRienz, R.T., Baker, D.D., Casavant, M., Spiller, H.A., Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?. Clinical Toxicology (Philadelphia) 54:5 (2016), 420–423, 10.3109/15563650.2016.1157722.
14. Caudevilla, F., Ventura, M., Fornis, I., Barratt, M.J., Vidal, C., Lladanosa, C.G., Calzada, N., Results of an international drug testing service for cryptomarket users. International Journal of Drug Policy 35 (2016), 38–41, 10.1016/j.drugpo.2016.04.017.
15. CDC, Influx of fentanyl-laced counterfeit pills and toxic fentanyl-related compounds further increases risk of fentanyl-related overdose and fatalities. 2016 Retrieved from.
16. Centers for Disease C & Prevention, Nonpharmaceutical fentanyl-related deaths–multiple states, April 2005–March 2007. MMWR Morbidity and Mortality Weekly Report 57:29 (2008), 793–796.
17. Centers for Disease C & Prevention, Vital signs: overdoses of prescription opioid pain relievers–United States, 1999–2008. MMWR Morbidity and Mortality Weekly Report 60:43 (2011), 1487–1492.
18. Ciccarone, D., Ondocsin, J., Mars, S., Heroin uncertainties: Heroin uncertainties: Exploring users’ perceptions of fentanyl-adulterated and—substituted ‘heroin. International Journal of Drug Policy 46 (2017), 146–155.
19. Cicero, T.J., Ellis, M.S., Surratt, H.L., Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine 367:2 (2012), 187–189, 10.1056/NEJMc1204141.
20. Clark, A.K., Wilder, C.M., Winstanley, E.L., A systematic review of community opioid overdose prevention and naloxone distribution programs. Journal of Addiction Medicine 8:3 (2014), 153–163, 10.1097/ADM.0000000000000034.
21. Coffin, P.O., Behar, E., Rowe, C., Santos, G.M., Coffa, D., Bald, M., Vittinghoff, E., Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Annals of Internal Medicine 165:4 (2016), 245–252, 10.7326/M15-2771.
22. Coffin, P.O., Tracy, M., Bucciarelli, A., Ompad, D., Vlahov, D., Galea, S., Identifying injection drug users at risk of nonfatal overdose. Academic Emergency Medicine 14:7 (2007), 616–623, 10.1197/j.aem.2007.04.005.
23. Damon, W., Small, W., Anderson, S., Maher, L., Wood, E., Kerr, T., McNeil, R., ‘Crisis’ and ‘everyday’ initiators: A qualitative study of coercion and agency in the context of methadone maintenance treatment initiation. Drug & Alcohol Review, 2016, 10.1111/dar.12411.
24. Darke, S., Addiction classics. Addiction, 111(11), 2016, 10.1111/add.13530 1899.
25. Darke, S., Duflou, J., The toxicology of heroin-related death: Estimating survival times. Addiction 111:9 (2016), 1607–1613, 10.1111/add.13429.
26. Darke, S., Hall, W., Weatherburn, D., Lind, B., Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug and Alcohol Dependence 54:2 (1999), 155–161.
27. Dart, R.C., Surratt, H.L., Cicero, T.J., Parrino, M.W., Severtson, S.G., Bucher-Bartelson, B., Green, J.L., Trends in opioid analgesic abuse and mortality in the United States. New England Journal of Medicine 372:3 (2015), 241–248, 10.1056/NEJMsa1406143.
28. Data brief: opioid-related overdose deaths among Massachusetts residents. (2016). Retrieved from: http://www.mass.gov/eohhs/docs/dph/stop-addiction/current-statistics/data-brief-overdose-deaths-nov-2016-ma-residents.pdf (Accessed 13 February 2017).
29. Davis, C.S., Southwell, J.K., Niehaus, V.R., Walley, A.Y., Dailey, M.W., Emergency medical services naloxone access: A national systematic legal review. Academic Emergency Medicine 21:10 (2014), 1173–1177, 10.1111/acem.12485.
30. Delcher, C., Wagenaar, A.C., Goldberger, B.A., Cook, R.L., Maldonado-Molina, M.M., Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug and Alcohol Dependence 150 (2015), 63–68, 10.1016/j.drugalcdep.2015.02.010.
31. Dettmer, K., Saunders, B., Strang, J., Take home naloxone and the prevention of deaths from opiate overdose: Two pilot schemes. BMJ 322:7291 (2001), 895–896.
32. Doe-Simkins, M., Walley, A.Y., Epstein, A., Moyer, P., Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose. American Journal of Public Health 99:5 (2009), 788–791, 10.2105/AJPH.2008.146647.
33. Dowell, D., Haegerich, T.M., Chou, R., CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recommendations and Reports 65:1 (2016), 1–49, 10.15585/mmwr.rr6501e1.
34. Drug Checking Day. (2017).
35. EcstasyData. (2017).
36. Fischer, B., Argento, E., Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician Journal 15:3 Suppl (2012), ES191–203.
37. Gaeta, J., Bock, B., Takach, M., Providing a safe space and medical monitoring to prevent overdose deaths. Health Affairs Blog, 2016 Retrieved from: http://healthaffairs.org/blog/2016/08/31/providing-a-safe-space-and-medical-monitoring-to-prevent-overdose-deaths/ (Accessed 5 March 2017) August 31.
38. Green, T.C., Gilbert, M., Counterfeit medications and fentanyl. JAMA Internal Medicine 176:10 (2016), 1555–1557, 10.1001/jamainternmed.2016.4310.
39. Green, T.C., Heimer, R., Grau, L.E., Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 103:6 (2008), 979–989, 10.1111/j.1360-0443.2008.02182.x.
40. Green, T.C., Zaller, N., Rich, J., Bowman, S., Friedmann, P., Revisiting Paulozzi et al.'s prescription drug monitoring programs and death rates from drug overdose. Pain Medicine 12:6 (2011), 982–985, 10.1111/j.1526-4637.2011.01136.x.
41. Henderson, G.L., Fentanyl-related deaths: Demographics, circumstances, and toxicology of 112 cases. Journal of Forensic Sciences 36:2 (1991), 422–433.
42. HHS takes strong steps to address opioid-drug related overdose, death and dependence. (March 26, 2015). [Press release]. Retrieved from: https://www.hhs.gov/about/news/2015/03/26/hhs-takes-strong-steps-to-address-opioid-drug-related-overdose-death-and-dependence.html (Accessed 5 March 2017).
43. Hospitalizations and Emergency Department Visits Due to Opioid Poisoning in Canada. (2016). Retrieved from Ottawa, ON.
44. Illicit Drug Overdose Deaths in BC January 1, 2007–October 31, 2016. (2016). Retrieved from.
45. Illicit Drug Overdose Deaths in BC, January 1, 2007–December 31, 2016. (2016). Retrieved from Burnaby, BC.
46. Jones, C.M., Lurie, P.G., Compton, W.M., Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. American Journal of Public Health 106:4 (2016), 689–690, 10.2105/AJPH.2016.303062.
47. Kennedy-Hendricks, A., Richey, M., McGinty, E.E., Stuart, E.A., Barry, C.L., Webster, D.W., Opioid overdose deaths and Florida's crackdown on pill mills. American Journal of Public Health 106:2 (2016), 291–297, 10.2105/AJPH.2015.302953.
48. Klar, S.A., Brodkin, E., Gibson, E., Padhi, S., Predy, C., Green, C., Lee, V.1, Notes from the field: Furanyl-Fentanyl overdose events caused by smoking contaminated crack cocaine—British Columbia, Canada, July 15–18, 2016. MMWR Morbidity and Mortality Weekly Report 65:37 (2016), 1015–1016, 10.15585/mmwr.mm6537a6.
49. Lab test confirms carfentanil is being ingested. (2017). [Press release]. Retrieved from: https://news.gov.bc.ca/releases/2017HLTH0020-000224 (Accessed 9 February 2017).
50. Larochelle, M.R., Zhang, F., Ross-Degnan, D., Wharam, J.F., Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Internal Medicine 175:6 (2015), 978–987, 10.1001/jamainternmed.2015.0914.
51. Lavonas, E.J., Drennan, I.R., Gabrielli, A., Heffner, A.C., Hoyte, C.O., Orkin, A.M., Donnino, M.W., Part 10: Special circumstances of resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 132:18 Suppl. 2 (2015), S501–S518, 10.1161/CIR.0000000000000264.
52. Lurie, P. (2016). FDA's Naloxone App Prize Competition Celebrates Innovation In Search of Technological Solutions to the Opioid Epidemic. Retrieved from: http://blogs.fda.gov/fdavoice/index.php/2016/12/fdas-naloxone-app-prize-competition-celebrates-innovation-in-search-of-technological-solutions-to-the-opioid-epidemic/ (Accessed 9 February 2017).
53. Macmadu, A., Carroll, J.J., Hadland, S.E., Green, T.C., Marshall, B.D., Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically. Addictive Behaviors 68 (2017), 35–38, 10.1016/j.addbeh.2017.01.014.
54. Mars, S.G., Bourgois, P., Karandinos, G., Montero, F., Ciccarone, D., Every ‘never’ I ever said came true: Transitions from opioid pills to heroin injecting. International Journal of Drug Policy 25:2 (2014), 257–266, 10.1016/j.drugpo.2013.10.004.
55. Marshall, B.D., Milloy, M.J., Wood, E., Montaner, J.S., Kerr, T., Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: A retrospective population-based study. The Lancet 377:9775 (2011), 1429–1437, 10.1016/S0140-6736(10)62353-7.
56. Martin, M., Hecker, J., Clark, R., Frye, J., Jehle, D., Lucid, E.J., Harchelroad, F., China White epidemic: An eastern United States emergency department experience. Annals of Emergency Medicine 20:2 (1991), 158–164.
57. Maxwell, S., Bigg, D., Stanczykiewicz, K., Carlberg-Racich, S., Prescribing naloxone to actively injecting heroin users: A program to reduce heroin overdose deaths. Journal of Addictive Diseases 25:3 (2006), 89–96, 10.1300/J069v25n03_11.
58. Mcelroy, J., Drugs tested at insite, 86% contain fentanyl. 2016, CBC News Retrieved from: http://www.cbc.ca/news/canada/british-columbia/insite-vancouver-coastal-health-fentanyl-free-drug-test-1.3741858 (Accessed 13 February 2017).
59. The Mobile Monitoring of Vital Signs in Opioid Users (MOVE). (2015) Retrieved from: https://clinicaltrials.gov/ct2/show/NCT02647073 (Accessed 9 February 2017).
60. Modarai, F., Mack, K., Hicks, P., Benoit, S., Park, S., Jones, C., Paulozzi, L., Relationship of opioid prescription sales and overdoses, North Carolina. Drug and Alcohol Dependence 132:1–2 (2013), 81–86, 10.1016/j.drugalcdep.2013.01.006.
61. Monforte, J.R., Some observations concerning blood morphine concentrations in narcotic addicts. Journal of Forensic Science 22:4 (1977), 718–724.
62. Murphy, Y., Goldner, E.M., Fischer, B., Prescription opioid use, harms and interventions in Canada: A review update of new developments and findings since 2010. Pain Physician 18:4 (2015), E605–E614.
63. Neale, J., Strang, J., Naloxone–does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. Addiction 110:10 (2015), 1644–1652, 10.1111/add.13027.
64. Oliva, E.M., Nevedal, A., Lewis, E.T., McCaa, M.D., Cochran, M.F., Konicki, P.E., Wilder, C., Patient perspectives on an opioid overdose education and naloxone distribution program in the U.S. Department of Veterans Affairs. Substance Abuse 37:1 (2016), 118–126, 10.1080/08897077.2015.1129528.
65. Oluwajenyo Banjo, M., Tzemis, D., Al-Qutub, D., Amlani, A., Kesselring, S., Buxton, J.A., A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program. CMAJ Open 2:3 (2014), E153–E161, 10.9778/cmajo.20140008.
66. Oviedo-Joekes, E., Brissette, S., Marsh, D.C., Lauzon, P., Guh, D., Anis, A., Schechter, M.T., Diacetylmorphine versus methadone for the treatment of opioid addiction. New England Journal of Medicine 361:8 (2009), 777–786, 10.1056/NEJMoa0810635.
67. Oviedo-Joekes, E., Guh, D., Brissette, S., Marchand, K., MacDonald, S., Lock, K., Schechter, M.T., Hydromorphone compared with diacetylmorphine for long-term opioid dependence: A randomized clinical trial. JAMA Psychiatry 73:5 (2016), 447–455, 10.1001/jamapsychiatry.2016.0109.
68. Paulozzi, L.J., Kilbourne, E.M., Desai, H.A., Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine 12:5 (2011), 747–754, 10.1111/j.1526-4637.2011.01062.x.
69. Peterson, A.B., Gladden, R.M., Delcher, C., Spies, E., Garcia-Williams, A., Wang, Y., Goldberger, B.A., Increases in fentanyl-related overdose deaths—Florida and Ohio, 2013–2015. MMWR Morbidity and Mortality Weekly Report 65:33 (2016), 844–849, 10.15585/mmwr.mm6533a3.
70. Piercefield, E., Archer, P., Kemp, P., Mallonee, S., Increase in unintentional medication overdose deaths: Oklahoma, 1994–2006. American Journal of Preventive Medicine 39:4 (2010), 357–363, 10.1016/j.amepre.2010.05.016.
71. Rudd, R.A., Aleshire, N., Zibbell, J.E., Gladden, R.M., Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morbidity and Mortality Weekly Report 64:50-51 (2016), 1378–1382, 10.15585/mmwr.mm6450a3.
72. Rudd, R.A., Seth, P., David, F., Scholl, L., Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morbidity and Mortality Weekly Report 65:5051 (2016), 1445–1452, 10.15585/mmwr.mm655051e1.
73. Rutkow, L., Chang, H.Y., Daubresse, M., Webster, D.W., Stuart, E.A., Alexander, G.C., Effect of Florida's prescription drug monitoring program and Pill Mill Laws on opioid prescribing and use. JAMA Internal Medicine 175:10 (2015), 1642–1649, 10.1001/jamainternmed.2015.3931.
74. Samuels, E., Emergency department naloxone distribution: a Rhode Island department of health, recovery community, and emergency department partnership to reduce opioid overdose deaths. Rhode Island Medical Journal (2013) 97:10 (2014), 38–39.
75. San Francisco Sentinel Community Site (SCS) Drug Use Patterns and Trends, 2016. (2016). Retrieved from.
76. SBIR Phase I—Automated Naloxone Delivery System. (2012).
77. Schwartz, R.P., Gryczynski, J., O'Grady, K.E., Sharfstein, J.M., Warren, G., Olsen, Y., Jaffe, J.H., Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009. American Journal of Public Health 103:5 (2013), 917–922, 10.2105/AJPH.2012.301049.
78. Seal, K.H., Downing, M., Kral, A.H., Singleton-Banks, S., Hammond, J.P., Lorvick, J., Edlin, B.R., Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: A survey of street-recruited injectors in the San Francisco Bay Area. Journal of Urban Health 80:2 (2003), 291–301, 10.1093/jurban/jtg032.
79. Seal, K.H., Thawley, R., Gee, L., Bamberger, J., Kral, A.H., Ciccarone, D., Edlin, B.R., Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: A pilot intervention study. Journal of Urban Health 82:2 (2005), 303–311, 10.1093/jurban/jti053.
80. Shafer, E., Bergeron, N., Smith-Ray, R., Robson, C., O'Koren, R., A nationwide pharmacy chain responds to the opioid epidemic. Journal of American Pharmacists Association (2003) 57:2S (2017), S123–S129, 10.1016/j.japh.2016.12.075.
81. Shah, N.G., Lathrop, S.L., Reichard, R.R., Landen, M.G., Unintentional drug overdose death trends in New Mexico, USA, 1990–2005: Combinations of heroin, cocaine, prescription opioids and alcohol. Addiction 103:1 (2008), 126–136, 10.1111/j.1360-0443.2007.02054.x.
82. Somerville, N.J., O'Donnell, J., Gladden, R.M., Zibbell, J.E., Green, T.C., Younkin, M., Walley, A.Y., Characteristics of fentanyl overdose—Massachusetts, 2014–2016. MMWR Morbidity and Mortality Weekly Report 66:14 (2017), 382–386, 10.15585/mmwr.mm6614a2.
83. Stopka, T.J., Donahue, A., Hutcheson, M., Green, T.C., Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015. J Am Pharm Assoc (2003)., 2017, 10.1016/j.japh.2016.12.077.
84. Sutter, M.E., Gerona, R.R., Davis, M.T., Roche, B.M., Colby, D.K., Chenoweth, J.A., Albertson, T.E., Fatal fentanyl: One pill can kill. Academic Emergency Medicine 24:1 (2017), 106–113, 10.1111/acem.13034.
85. Suzuki, J., El-Haddad, S., A review: Fentanyl and non-pharmaceutical fentanyls. Drug and Alcohol Dependence 171 (2017), 107–116, 10.1016/j.drugalcdep.2016.11.033.
86. Tobin, K.E., Sherman, S.G., Beilenson, P., Welsh, C., Latkin, C.A., Evaluation of the Staying Alive programme: Training injection drug users to properly administer naloxone and save lives. International Journal of Drug Policy 20:2 (2009), 131–136, 10.1016/j.drugpo.2008.03.002.
87. Tomassoni, A.J., Hawk, K.F., Jubanyik, K., Nogee, D.P., Durant, T., Lynch, K.L., D'Onofrio, G., Multiple fentanyl overdoses – New Haven, Connecticut, June 23, 2016. MMWR Morbidity and Mortality Weekly Report 66:4 (2017), 107–111, 10.15585/mm6604a4.
88. Trescot, A.M., Datta, S., Lee, M., Hansen, H., Opioid pharmacology. Pain Physician 11:2 Suppl (2008), S133–153.
89. Unick, G.J., Rosenblum, D., Mars, S., Ciccarone, D., Intertwined epidemics: National demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993–2009. Public Library of Science, 8(2), 2013, 10.1371/journal.pone.0054496 e54496.
90. Visconti, A.J., Santos, G.M., Lemos, N.P., Burke, C., Coffin, P.O., Opioid overdose deaths in the city and county of San Francisco: Prevalence, distribution, and disparities. Journal of Urban Health 92:4 (2015), 758–772, 10.1007/s11524-015-9967-y.
91. Wagner, K.D., Davidson, P.J., Iverson, E., Washburn, R., Burke, E., Kral, A.H., Lankenau, S.E., I felt like a superhero: The experience of responding to drug overdose among individuals trained in overdose prevention. International Journal of Drug Policy 25:1 (2014), 157–165, 10.1016/j.drugpo.2013.07.003.
92. Wagner, K.D., Valente, T.W., Casanova, M., Partovi, S.M., Mendenhall, B.M., Hundley, J.H., Unger, J.B., Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. International Journal of Drug Policy 21:3 (2010), 186–193, 10.1016/j.drugpo.2009.01.003.
93. Walley, A.Y., Doe-Simkins, M., Quinn, E., Pierce, C., Xuan, Z., Ozonoff, A., Opioid overdose prevention with intranasal naloxone among people who take methadone. Journal of Substance Abuse Treatment 44:2 (2013), 241–247, 10.1016/j.jsat.2012.07.004.
94. Walley, A.Y., Xuan, Z., Hackman, H.H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ozonoff, A., Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. British Medical Journal, 346, 2013, f174.
95. Wheeler, E., Jones, T.S., Gilbert, M.K., Davidson, P.J., Centers for Disease, C., & Prevention, Opioid Overdose Prevention Programs Providing Naloxone to Laypersons ? United States, 2014. MMWR Morbidity and Mortality Weekly Report 64:23 (2015), 631–635.
96. Wilkins, L., Formica, S. W., Ruiz, S., Reilly, B., Apsler, R., & Walley, A. Y. (2016). Post-Opioid Overdose Follow-up Programs by Police and Fire Departments in Massachusetts [abstract Supp 1]. In: Gordon, A. The 40th Annual Meeting of AMERSA − Highlights, Abstracts and Awards. Substance Abuse, 38(1).
97. Wolfson-Stofko, B., Bennett, A.S., Elliott, L., Curtis, R., Drug use in business bathrooms: An exploratory study of manager encounters in New York City. International Journal of Drug Policy 39 (2017), 69–77, 10.1016/j.drugpo.2016.08.014.
98. Woo, A., Mobile Medical Unit brings hope, relief to B.C. overdose victims. 2017 Retrieved from: http://www.theglobeandmail.com/news/british-columbia/mobile-medical-unit-brings-hope-relief-to-bc-overdose-victims/article33469434/ (Accessed 13 February 2017).